Accepted
at 8:39 p.m. Oct, 23, 2023
by
Ahmed7
Bulk Suggestion
Bulk ID:
zarathustra/10.21.23-07:06PM
Author:
zarathustra
Co-authors:
Cameron
Type of change:
Updated content
Rationale for change
per AMBOSS, Nirsevimab is now preferred over Palivizumab (approved by FDA, July 2023)
Source: AMBOSS - https://www.amboss.com/us/knowledge/bronchiolitis/
Before
After
Extra
Extra
Extra
Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field